Krazati
What Krazati is used for
Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Krazati
- Active substance
- adagrasib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Other antineoplastic agents
- ATC code
- L01XX77
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Krazati used for?
Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
What is the active substance in Krazati?
Krazati contains adagrasib.
Who makes Krazati?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU